leukemia

[Frontiers in Oncology] Investigators found that AML cells released a heterogeneous population of extracellular vesicles containing microRNAs involved in AML pathogenesis.

[Haematologica] The study comprises children with persistent cytopenias, myelodysplastic syndrome, aplastic anemia, or suspected inherited bone marrow failure syndromes, who were referred for genetic evaluation from all pediatric hematology centers in Israel during 2016-2019.

[Journal of Hematology & Oncology] The role of wild-type isocitrate dehydrogenase-2 (IDH2) in AML cell survival and proliferation was tested using genetic knockdown and pharmacological inhibition in AML cells and animal models.

[Cancer] To explore the efficacy of sorafenib combined with conventional therapies for refractory central nervous system leukemia, a Phase II study was conducted.

[Cancer Discovery] In models of AML, leukemia cell differentiation and therapeutic benefit mediated by the histone deacetylases inhibitor panobinostat required activation of the type I interferon pathway.

[Cancer Research] The authors established cells with acquired resistance to the allosteric SHP2 inhibitor SHP099 from two FLT3-ITD-positive AML cell lines.